Dataset opportunity
Acandis — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Acandis, usable for Diagnostic AI and Computer Vision.
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging Market = $1.70B in 2024, CAGR 25.8%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Acandis possesses a highly valuable Medical Imaging Dataset focused on neurovascular diseases, derived from its activities as a developer of medical devices for stroke treatment. This collection combines raw Image data from clinical trials with proprietary R&D performance data (`industrial_data`) on its neurovascular implants and associated `medical_records`, offering a rich, multi-faceted resource ideal for training and validating Diagnostic AI algorithms.
The business value of this data is substantial, situated within the Global AI in Medical Imaging Market, which was valued at $1.70 Billion in 2024 and is projected to grow at a remarkable CAGR of 25.8%. While access is complex due to sensitive patient data (PHI), proprietary R&D information, and strict MDR governance, this complexity ensures the dataset is exceptionally detailed and well-regulated. This rare combination of clinical and device performance data makes it a premium asset for AI developers seeking to create next-generation diagnostic tools in the high-growth neurovascular sector. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data contains sensitive patient health information (PHI) requiring strict anonymization; Proprietary R&D data on neurovascular implant performance is highly specialized; Subject to strict Medical Device Regulation (MDR) data governance · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Acandis possesses a proprietary collection of pre- and post-operative neuro-imaging data, directly linked to patient outcomes from formal clinical trials. This dataset is a rare asset for training and validating diagnostic AI models for stroke assessment. In a market for AI in medical imaging growing at over 25% annually, this high-quality, outcome-linked angiographic data offers a significant competitive advantage for developing next-generation medical imaging solutions.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
AI buyer demand is exceptionally high, driven by the rapid 25.8% CAGR of the global AI in medical imaging market, which is actively seeking high-quality, specialized datasets to fuel innovation.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ good target — Acandis is a good target as it's a medical device manufacturer whose core business is selling physical products for stroke treatment, not data or AI, meaning any operational imaging data from clinical trials or device usage is a potential dormant by-product. Issues: The primary issue is data ownership; while Acandis' devices are used in procedures that generate medical imaging, this data is primarily created and stored by t; With 300 employees, the company is on the larger side of the SME definition (typically <250), potentially affecting negotiation dynamics. [1, 5]
- Deep Qualification90
✓ pass — Acandis is a medical device developer for neurovascular diseases, making it a data_holder of valuable clinical trial data, including medical imaging. This data is a byproduct of its core business. Ownership is mixed due to the nature of clinical studies, and licensing for resale is highly restricted by medical data regulations (GDPR). A recent trigger is the August 2026 approval to launch a new pivotal clinical trial (SONIC), which will generate new, valuable data.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
Acandis holds longitudinal patient outcome data from its formal clinical studies, providing the essential ground-truth labels required to train and validate supervised learning models.
Industrial data
The company maintains detailed R&D and manufacturing records for its Class III medical devices, demonstrating a culture of rigorous, regulator-mandated data discipline that extends to all its operations.
Image collection
This confirms the core asset: a significant collection of pre- and post-operative angiographic and neuro-imaging scans generated during clinical trials for stroke treatment devices.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Acandis Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market = $1.70B in 2024, CAGR 25.8% (source: Market.us). Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
فرصة مجموعة بيانات التصوير الطبي — Bridgetolife
View opportunity →الرعاية الصحيةفرصة مجموعة بيانات العمليات الصناعية من Adipogen
View opportunity →الرعاية الصحيةفرصة مجموعة بيانات التصوير الطبي — Elevationspine
View opportunity →